

Szu-Chun Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9153885/publications.pdf>

Version: 2024-02-01

39
papers

433
citations

759233

12
h-index

794594

19
g-index

40
all docs

40
docs citations

40
times ranked

783
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2022, 13, 182-189.	1.9	3
2	The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. <i>Scientific Reports</i> , 2022, 12, 3319.	3.3	7
3	Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 85.	2.0	2
4	Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 774-782.e4.	4.9	4
5	Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008-2016. <i>Journal of General Internal Medicine</i> , 2021, 36, 3589-3591.	2.6	1
6	Downstream Complications and Healthcare Expenditure after Invasive Procedures for Lung Lesions in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4040.	2.6	3
7	QALYs and medical costs saved from prevention of a cancer: Analysis of nation-wide real-world data of Taiwan with lifetime horizon. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2089-2099.	1.7	5
8	Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. <i>Scientific Reports</i> , 2021, 11, 12180.	3.3	11
9	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 671127.	2.8	2
10	Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. <i>Lung Cancer</i> , 2021, 158, 137-145.	2.0	6
11	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1729-1739.	1.7	9
12	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 760686.	2.8	8
13	Life expectancy (LE) and loss-of-LE for patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2020, 172, 106132.	2.9	5
14	Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. <i>BMJ Open</i> , 2020, 10, e033427.	1.9	14
15	Indigenous recurrent disseminated histoplasmosis in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 1047-1049.	3.1	4
16	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. <i>PLoS ONE</i> , 2020, 15, e0231413.	2.5	10
17	Title is missing!. , 2020, 15, e0231413.		0
18	Title is missing!. , 2020, 15, e0231413.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0231413.		0
20	Title is missing!. , 2020, 15, e0231413.		0
21	Title is missing!. , 2020, 15, e0231413.		0
22	Title is missing!. , 2020, 15, e0231413.		0
23	Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment. <i>Cancer Medicine</i> , 2019, 8, 5939-5947.	2.8	12
24	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1892-1900.	1.1	16
25	Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. <i>BMJ Open</i> , 2019, 9, e022293.	1.9	9
26	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401875507.	3.2	13
27	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879758.	3.2	41
28	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. <i>PLoS ONE</i> , 2018, 13, e0192161.	2.5	26
29	Diminishing marginal cost-effectiveness in risk-targeted lung cancer screening. <i>Translational Cancer Research</i> , 2018, 7, 1310-1312.	1.0	0
30	Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Life-Brief among lung cancer patients. <i>Journal of Health Psychology</i> , 2017, 22, 397-408.	2.3	37
31	Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. <i>Lung Cancer</i> , 2017, 108, 183-191.	2.0	49
32	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. <i>Oncotarget</i> , 2017, 8, 18590-18608.	1.8	52
33	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. <i>Quality of Life Research</i> , 2016, 25, 1441-1449.	3.1	15
34	Comparison of Global Initiative for Chronic Obstructive Pulmonary Disease 2013 Classification and Body Mass Index, Airflow Obstruction, Dyspnea, and Exacerbations Index in Predicting Mortality and Exacerbations in Elderly Adults with Chronic Obstructive Pulmonary Disease. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 244-250.	2.6	14
35	Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: Adjusting quality-of-life and lead-time bias for utility of surgery. <i>Lung Cancer</i> , 2014, 86, 96-101.	2.0	18
36	Estimating the lifelong health impact and financial burdens of different types of lung cancer. <i>BMC Cancer</i> , 2013, 13, 579.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Positive blood culture is not associated with increased mortality in patients with sepsis-induced acute respiratory distress syndrome. <i>Respirology</i> , 2013, 18, 1210-1216.	2.3	13
38	Germ Cell Tumor With Somatic-Type Malignancy Presenting As Right Facial Swelling in a Young Woman. <i>Journal of Clinical Oncology</i> , 2011, 29, e699-e701.	1.6	0
39	PM _{2.5} exposure and risk of lung adenocarcinoma in women of Taiwan: A case-control study with density sampling. <i>Respirology</i> , 0, , .	2.3	3